Teva Pharmaceutical (TEVA) Tops Q1 EPS by 3c, Sales Light
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical (NASDAQ: TEVA) reported Q1 EPS of $1.47, $0.03 better than the analyst estimate of $1.44. Revenue for the quarter rose 25% to $5.1 billion versus the consensus estimate of $5.51 billion.
For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.
For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- IDEX Corp. (IEX) Tops Q1 EPS by 13c ; Offers Guidance
- Visa (V) earnings and revenue exceed estimates in Q2, shares rise
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!